Grzegorz S. Nowakowski, MD
Although considerable progress has been made in treating diffuse large B-cell lymphoma (DLBCL) since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory (R/R) disease, which is associated with considerable morbidity and mortality.1
Several treatment options exist for this patient population including high-dose therapy and transplant, as well as chimeric antigen receptor (CAR) T-cell therapy. However, as patients progress through treatments, options in subsequent lines of therapy dwindle, particularly if they are ineligible for transplant. This dilemma has led to the search for novel therapeutic approaches for patients whose disease fails to respond to currently available therapies.
... to read the full story